Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OCC
OCC logo

OCC Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Optical Cable Corp (OCC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
22.400
1 Day change
3.08%
52 Week Range
27.980
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Optical Cable Corp (OCC) does not present a compelling buy opportunity at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. The lack of significant trading trends, recent news, or positive catalysts, combined with no proprietary trading signals, suggests a neutral stance. Additionally, the technical indicators, while showing some bullish signs, do not strongly support an immediate buy decision.

Technical Analysis

The MACD histogram is positive at 0.353 and contracting, indicating a potential slowdown in momentum. RSI at 62.084 is neutral, suggesting no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), which is a positive sign. Key support and resistance levels are Pivot: 20.281, R1: 26.461, S1: 14.1, R2: 30.28, S2: 10.281. However, the stock's trend prediction indicates a 40% chance of minor gains in the next day but potential declines in the next week (-2.54%) and month (-8.56%).

Positive Catalysts

  • Bullish moving averages and a positive MACD histogram suggest some upward momentum.

Neutral/Negative Catalysts

  • No significant news, trading trends, or recent congress trading data. Stock trend analysis suggests potential declines in the next week and month.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available.

Wall Street analysts forecast OCC stock price to rise
Analyst Rating
0
Wall Street analysts forecast OCC stock price to rise
Buy
Hold
Sell
0
Current: 21.730
sliders
Low
0
Averages
0
High
0
0
Current: 21.730
sliders
Low
0
Averages
0
High
0
Canaccord
Shane Storey
Speculative Buy
initiated
$1.33
AI Analysis
2025-12-17
Reason
Canaccord
Shane Storey
Price Target
$1.33
AI Analysis
2025-12-17
initiated
Speculative Buy
Reason
Canaccord analyst Shane Storey initiated coverage of Orthocell with a Speculative Buy rating and A$1.33 price target. The regenerative medicine company is commercializing novel collagen-based devices for peripheral nerve repair, including its flagship product, Remplir, the analyst tells investors. Recently achieved key global clearances, including FDA 510(k) clearance in April, position the company "at the start of a multi-year commercial expansion," the analyst added.

People Also Watch